S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.71 (+2.15%)
AAPL   160.65 (+1.79%)
MSFT   280.16 (+2.89%)
META   206.27 (+3.23%)
GOOGL   105.99 (+2.53%)
AMZN   100.28 (+1.60%)
TSLA   195.73 (+2.40%)
NVDA   273.70 (+3.41%)
NIO   9.33 (+2.64%)
BABA   86.99 (+3.99%)
AMD   101.74 (+4.26%)
T   18.50 (+0.60%)
F   11.65 (+1.48%)
MU   61.02 (+4.90%)
CGC   1.91 (+1.59%)
GE   92.17 (+2.88%)
DIS   96.77 (+1.97%)
AMC   4.54 (+4.61%)
PFE   40.43 (+1.05%)
PYPL   73.32 (-1.37%)
NFLX   319.45 (+8.69%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.71 (+2.15%)
AAPL   160.65 (+1.79%)
MSFT   280.16 (+2.89%)
META   206.27 (+3.23%)
GOOGL   105.99 (+2.53%)
AMZN   100.28 (+1.60%)
TSLA   195.73 (+2.40%)
NVDA   273.70 (+3.41%)
NIO   9.33 (+2.64%)
BABA   86.99 (+3.99%)
AMD   101.74 (+4.26%)
T   18.50 (+0.60%)
F   11.65 (+1.48%)
MU   61.02 (+4.90%)
CGC   1.91 (+1.59%)
GE   92.17 (+2.88%)
DIS   96.77 (+1.97%)
AMC   4.54 (+4.61%)
PFE   40.43 (+1.05%)
PYPL   73.32 (-1.37%)
NFLX   319.45 (+8.69%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.71 (+2.15%)
AAPL   160.65 (+1.79%)
MSFT   280.16 (+2.89%)
META   206.27 (+3.23%)
GOOGL   105.99 (+2.53%)
AMZN   100.28 (+1.60%)
TSLA   195.73 (+2.40%)
NVDA   273.70 (+3.41%)
NIO   9.33 (+2.64%)
BABA   86.99 (+3.99%)
AMD   101.74 (+4.26%)
T   18.50 (+0.60%)
F   11.65 (+1.48%)
MU   61.02 (+4.90%)
CGC   1.91 (+1.59%)
GE   92.17 (+2.88%)
DIS   96.77 (+1.97%)
AMC   4.54 (+4.61%)
PFE   40.43 (+1.05%)
PYPL   73.32 (-1.37%)
NFLX   319.45 (+8.69%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.71 (+2.15%)
AAPL   160.65 (+1.79%)
MSFT   280.16 (+2.89%)
META   206.27 (+3.23%)
GOOGL   105.99 (+2.53%)
AMZN   100.28 (+1.60%)
TSLA   195.73 (+2.40%)
NVDA   273.70 (+3.41%)
NIO   9.33 (+2.64%)
BABA   86.99 (+3.99%)
AMD   101.74 (+4.26%)
T   18.50 (+0.60%)
F   11.65 (+1.48%)
MU   61.02 (+4.90%)
CGC   1.91 (+1.59%)
GE   92.17 (+2.88%)
DIS   96.77 (+1.97%)
AMC   4.54 (+4.61%)
PFE   40.43 (+1.05%)
PYPL   73.32 (-1.37%)
NFLX   319.45 (+8.69%)
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

$39.39
-0.30 (-0.76%)
(As of 03/23/2023 12:41 PM ET)
Add
Compare
Today's Range
$38.86
$40.45
50-Day Range
$39.69
$54.59
52-Week Range
$37.59
$79.50
Volume
68,563 shs
Average Volume
175,406 shs
Market Capitalization
$822.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.60

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
70.3% Upside
$68.60 Price Target
Short Interest
Healthy
3.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.18mentions of Enanta Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.36) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

193rd out of 986 stocks

Pharmaceutical Preparations Industry

79th out of 477 stocks


ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Expert Ratings for Enanta Pharma
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
SVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
2/07/2023
Today
3/23/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$68.60
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+72.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-121,750,000.00
Net Margins
-146.93%
Pretax Margin
-147.46%

Debt

Sales & Book Value

Annual Sales
$86.16 million
Book Value
$15.51 per share

Miscellaneous

Free Float
18,233,000
Market Cap
$829.12 million
Optionable
Optionable
Beta
0.40

Key Executives

  • Jay R. LulyJay R. Luly
    President, Chief Executive Officer & Director
  • Paul J. Mellett
    CFO & Senior VP-Finance & Administration
  • Yat Sun Or
    CSO, Senior Vice President-Research & Development
  • Scott T. Rottinghaus
    Chief Medical Officer & Senior Vice President
  • Nathaniel S. Gardiner
    Secretary, Senior Vice President & General Counsel













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2023?

9 brokerages have issued 1 year target prices for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they predict the company's stock price to reach $68.60 in the next year. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2023?

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of the year. Since then, ENTA stock has decreased by 14.7% and is now trading at $39.69.
View the best growth stocks for 2023 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 750,300 shares, a decrease of 8.4% from the February 13th total of 819,500 shares. Based on an average trading volume of 155,700 shares, the short-interest ratio is presently 4.8 days. Currently, 3.9% of the shares of the stock are sold short.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Tuesday, February, 7th. The biotechnology company reported ($1.39) earnings per share for the quarter, beating analysts' consensus estimates of ($1.52) by $0.13. The biotechnology company had revenue of $23.60 million for the quarter, compared to analyst estimates of $22.48 million. Enanta Pharmaceuticals had a negative net margin of 146.93% and a negative trailing twelve-month return on equity of 36.59%. The company's revenue was down 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.48) earnings per share.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.95%), Dimensional Fund Advisors LP (2.60%), Renaissance Technologies LLC (2.27%), Geode Capital Management LLC (1.81%), Braidwell LP (1.56%) and Norges Bank (1.08%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $39.69.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $829.12 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.82) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 3/23/2023 by MarketBeat.com Staff